Medication info

Nexrica Capsule 25 mg (Pregabalin)

Prescription medicationHard capsuleOralExpired
Ingredient · strength
Pregabalin›25mg / 1 capsule
Manufacturer / importer
Nexpharm Korea Co., Ltd.
Appearance
A hard capsule with a pale yellow upper part and a white lower part containing white powder.
Packaging
30 capsules/bottle
Approval status
Expired

MFDS item code 202004145 · Approved 2020.05.31

This product's status changed to Expired on 2025.05.31. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
Who takes it
Adults · Children
Adult dose
This medication is administered orally, regardless of food, with the total daily dose of pregabalin divided into 2 doses. Since this medication is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See “5. Patients with Renal Impairment”) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: The initial dose of this medication may be 150 mg per day. Based on each patient’s response and tolerability, the dose may be increased to up to 300 mg per day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 2) Central Neuropathic Pain Adults: The initial dose of this medication may be 150 mg per day. Based on each patient’s response and tolerability, the dose may be increased to up to 300 mg per day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, a dose reduction may be considered. (See “4. Discontinuation of Treatment”) 2. Epilepsy Adults: The initial dose of this medication may be 150 mg per day. Based on each patient’s response and tolerability, the dose may be increased to up to 300 mg per day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg-450 mg per day. The initial dose is 75 mg twice daily (150 mg per day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies have also been conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medication is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medication is primarily excreted by the kidneys unchanged. Since the clearance of this medication is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. Creatinine clearance (mL/min)* = [140 – age (years)] x body weight (kg) 72 x serum creatinine concentration (serum creatinine, mg/dL) * For women, multiply the result obtained using the above formula by 0.85. This medication is effectively removed from plasma by hemodialysis. (Approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1] Pregabalin Dosage Based on Renal Function Creatinine clearance (CLcr), (mL/min) ≥60: Total daily dose of pregabalin: starting dose 150 (mg/day), maximum dose 600 (mg/day), dosing regimen BID or TID ≥30-<60: starting dose 75 (mg/day), maximum dose 300 (mg/day), dosing regimen BID or TID ≥15-<30: starting dose 25-50 (mg/day), maximum dose 150 (mg/day), dosing regimen QD or BID <15: starting dose 25 (mg/day), maximum dose 75 (mg/day), dosing regimen QD Supplemental dose after hemodialysis: starting dose 25, maximum dose 100, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the dosing regimen. b: The supplemental dose refers to a dose administered as a single additional dose. 6. Patients with Hepatic Impairment Dose adjustment is not necessary in patients with hepatic impairment. 8. Older Adults (65 years and older) Dose reduction may be necessary in older adults with impaired renal function.
Child dose
Children under 12 years of age: Use is not recommended because data on safety and efficacy are insufficient. Adolescents aged 12–17 years: Use is not recommended because data on safety and efficacy are insufficient.

Ingredients

Manufacturer
Nexpharm Korea Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used in adults to treat peripheral and central neuropathic pain. It is also used as an adjunct for partial seizures in adults with epilepsy, helping to control seizures. Additionally, it is effectively utilized for pain relief in patients with fibromyalgia. Overall, this medication improves the quality of life of patients by being used for neuropathic pain and seizure control.

How to take

Adult dose

This medication is administered orally, regardless of food, with the total daily dose of pregabalin divided into 2 doses. Since this medication is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See “5. Patients with Renal Impairment”) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: The initial dose of this medication may be 150 mg per day. Based on each patient’s response and tolerability, the dose may be increased to up to 300 mg per day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 2) Central Neuropathic Pain Adults: The initial dose of this medication may be 150 mg per day. Based on each patient’s response and tolerability, the dose may be increased to up to 300 mg per day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, a dose reduction may be considered. (See “4. Discontinuation of Treatment”) 2. Epilepsy Adults: The initial dose of this medication may be 150 mg per day. Based on each patient’s response and tolerability, the dose may be increased to up to 300 mg per day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg-450 mg per day. The initial dose is 75 mg twice daily (150 mg per day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies have also been conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medication is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medication is primarily excreted by the kidneys unchanged. Since the clearance of this medication is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. Creatinine clearance (mL/min)* = [140 – age (years)] x body weight (kg) 72 x serum creatinine concentration (serum creatinine, mg/dL) * For women, multiply the result obtained using the above formula by 0.85. This medication is effectively removed from plasma by hemodialysis. (Approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1] Pregabalin Dosage Based on Renal Function Creatinine clearance (CLcr), (mL/min) ≥60: Total daily dose of pregabalin: starting dose 150 (mg/day), maximum dose 600 (mg/day), dosing regimen BID or TID ≥30-<60: starting dose 75 (mg/day), maximum dose 300 (mg/day), dosing regimen BID or TID ≥15-<30: starting dose 25-50 (mg/day), maximum dose 150 (mg/day), dosing regimen QD or BID <15: starting dose 25 (mg/day), maximum dose 75 (mg/day), dosing regimen QD Supplemental dose after hemodialysis: starting dose 25, maximum dose 100, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the dosing regimen. b: The supplemental dose refers to a dose administered as a single additional dose. 6. Patients with Hepatic Impairment Dose adjustment is not necessary in patients with hepatic impairment. 8. Older Adults (65 years and older) Dose reduction may be necessary in older adults with impaired renal function.

Child dose

Children under 12 years of age: Use is not recommended because data on safety and efficacy are insufficient. Adolescents aged 12–17 years: Use is not recommended because data on safety and efficacy are insufficient.

Precautions

This medication may increase the risk of suicidal thoughts and behavior; therefore, mood or behavioral changes should be closely monitored during treatment. Patients with hypersensitivity to this medication, lactose intolerance, lactase deficiency, or glucose-galactose malabsorption should not use it. Patients with diabetes should be cautious as weight gain may require adjustment of glucose control medications. If symptoms such as facial and oral swelling or upper airway swelling occur, this medication should be discontinued immediately. Elderly patients may experience side effects such as dizziness, drowsiness, or loss of consciousness more readily; caution is especially necessary at the beginning of treatment. If vision blurring or changes in eyesight occur during treatment with this medication, symptoms may improve or disappear, but caution is advised. Abrupt discontinuation of this medication may result in withdrawal symptoms such as insomnia, headache, nausea, and anxiety; therefore, it should be gradually reduced under a doctor's guidance. There is a risk of drug abuse or dependence; thus, patients with a history of drug abuse should use this medication with caution. Patients with reduced kidney function may require dosage adjustment, and cases have been reported where kidney function improved after discontinuation of this medication. Patients with heart failure should use this medication with caution, and those with cardiac conditions should consult their doctors. The risk of drowsiness and respiratory depression increases when combined with other central nervous system depressants or alcohol, so caution is necessary. In early pregnancy, there is a risk of congenital malformations; therefore, women who are pregnant or planning to become pregnant should definitely consult a doctor. Breastfeeding women should consider that this medication may pass into breast milk, weighing the benefits of treatment against breastfeeding. Caution is advised during activities such as driving or operating machinery, as dizziness or drowsiness may occur due to this medication. Severe skin reactions (such as Stevens-Johnson syndrome) have been reported rarely; if skin rash or unusual symptoms appear, discontinue the medication immediately and consult a healthcare provider. This medication should be kept out of reach of children, and it is safer not to transfer it to another container. In the case of an overdose, symptoms such as drowsiness, confusion, depression, and seizures may occur, so it is essential to visit a healthcare institution for appropriate treatment.

Side effects

  • suicidal impulses
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • perioral edema
  • upper airway edema
  • dizziness
  • drowsiness
Show 174 more
  • loss of consciousness
  • confusion
  • mental disorders
  • blurred vision
  • changes in vision
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like syndrome
  • restlessness
  • suicidal thoughts
  • pain
  • seizures
  • perspiration
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • decreased respiratory function
  • vomiting
  • abdominal bloating
  • constipation
  • dry mouth
  • distension
  • excessive salivation
  • gastroesophageal reflux disease
  • impaired oral sensation
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweat
  • muscle cramps
  • joint pain
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle spasms
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urination disorders
  • urinary incontinence
  • decreased urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • breast pain
  • breast discharge
  • breast enlargement
  • peripheral edema
  • edema
  • gait abnormalities
  • falls
  • feeling intoxicated
  • sensory disturbances
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood sugar
  • decreased platelet count
  • decreased serum potassium
  • weight loss
  • increased serum creatinine
  • decreased white blood cell count
  • rhinopharyngitis
  • neutropenia
  • increased appetite
  • decreased appetite
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • depression
  • feelings of relief
  • decreased libido
  • depersonalization
  • sexual hyperesthesia
  • restlessness
  • anxiety
  • mood dysregulation
  • emotional lability
  • finding appropriate terms difficult
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • loss of impulse control
  • apathy
  • ataxia
  • impaired coordination
  • balance disorder
  • amnesia
  • attention deficit
  • memory impairment
  • tremors
  • dysarthria
  • sensory abnormalities
  • sensory loss
  • sedation
  • hypersomnia
  • cognitive impairment
  • nystagmus
  • speech disorders
  • focal muscle spasms
  • decreased reflexes
  • motor abnormalities
  • psychomotor agitation
  • positional dizziness
  • hypersensitivity
  • burning sensation
  • activity tremor
  • syncope
  • confusion
  • hypokinesia
  • olfactory disturbances
  • taste loss
  • writing difficulties
  • diplopia
  • auditory hypersensitivity
  • first-degree heart block
  • tachycardia
  • sinus bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • throat tension
  • nasal dryness
  • keratitis
  • pulmonary edema
  • tongue swelling
  • itchiness
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • delirium
  • paralysis (facial paralysis)
  • affective disorder
  • drowsiness
  • confused state
  • agitation
  • restlessness
  • seizures

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it should be stored in a tightly sealed container. It is recommended to maintain the storage temperature between 15 to 30 degrees Celsius.

Appearance and packaging

Appearance

A hard capsule with a pale yellow upper part and a white lower part containing white powder.

Package unit

30 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.